Ladies and gentlemen, good day and welcome to Q2 FY2025 earnings conference call of UPL Limited. As a reminder, all participant lines will be in the listen-only mode, and there will be an opportunity for you to ask questions after the presentation concludes. Should you need assistance during the conference call, please signal an operator by pressing star then zero on your touchtone phone. Please note that this conference is being recorded. I'll hand the conference over to Mr. Anurag Gupta, Head Investor Relations. Thank you, and over to you, sir.
Thank you, Rutuja. Good afternoon, everyone. Thanks for joining us today for the results for the second quarter and half year ending 30th September 2024. The presentation, press release, and the financial statements have been made available on the website, and we take it that you have read the safe harbor statement. From our management team, we have with us today Vice Chairman Rajendra Darak, CEO of our Global Crop Protection Business, Mike Frank, CFO Anand Vora, CEO of our India Crop Protection Platform, Ashish Dobhal, CEO of our seed business, Advanta, Bhupen Dubey, and CEO of our Specialty Chemicals Business, Raj Tiwari. With that, I now hand it over to Anand. Anand, over to you.
Thanks, Anurag. A very warm welcome to all of you who have joined us today. The business performance for Q2 shows a good recovery and provides confidence for meeting our guidance on revenue, EBITDA, and free cash flow for the full financial year. Let me take you through some key financial highlights for Quarter two . Revenue at INR 11,090 crores were up by 9% year-on-year on the back of strong volume growth of 16% and a negative 7% decline due to price. Contribution for Q2 stood at INR 4,180 crores, was up by 3% year-on-year, and contribution margin were at 37.7%, 220 basis points lower year-on-year, largely on account of drop-in prices and regional mix.
Selling general and administrative expenses, or SG&A as we call it, were at INR 2,604 crores, up by 5% year-on-year on back of one of our customer filing for Chapter 11, resulting in an increase in provision for expected credit loss, or ECL as we call it, in the LATAM region. Backing off this increase in ECL, SG&A for the quarter was nearly flat as compared to last year. The EBITDA for Q2 stood at INR 1,576 crores, flat versus last year, showing a good improvement compared to a 28% drop in the preceding quarter of this financial year. We saw an improvement in EBITDA margins from 12.6% in Q1 to 14.2% in Q2, an improvement of 160 basis points.
Profit After Tax adjusted for exceptional items, associated income, and minority interest showed a loss of INR 443 crores as compared to a loss of INR 189 crores in the previous year in the same quarter. One of the main factors contributing to the higher loss was the impact of income tax charge due to non-recognition of deferred tax asset, as well as reversal of DTA in some countries, which we had recognized in the previous year. For the quarter, we saw a marginal increase in depreciation and amortization finance costs on back of increase in SOFR rates and margin spread due to lowering of companies' ratings at the beginning of the financial year.
Foreign exchange charge, or FX losses, were at INR 375 crores, higher by INR 146 crores on the back of higher revenue and primarily on account of some of the countries where the cost of hedging was significantly higher or the banks had withdrawn their operations in those countries. Financial performance for H1, revenues stood at INR 20,157 crores, up by 5% year-on-year. Volumes were up by 16%, whereas we saw a price reduction by 10% and an exchange impact of 1%. Contribution at INR 7,764 crores was down year-on-year by 5%, largely due to pricing pressure and regional mix. The drop in contribution in Q2 year-on-year was much lower than that in Q1 year-on-year. SG&A at INR 5,043 crores were up by 1%, an increase in ECL provision being one of the large contributors to the increase. Adjusting for the ECL provision, the SG&A was lower by approximately 2%.
EBITDA at INR 2,721 crores showed a drop of 14% year-on-year. However, this showed a good improvement as compared to Q1 of this financial year, in which the EBITDA drop was as high as 28%. As mentioned earlier, we are seeing a continued improvement in EBITDA quarter on quarter, and based on the forecast we have for Q3 and full financial year, we expect to deliver the guidance of over 50% improvement by the end of this financial year. Profit after tax for H1 was a loss of INR 827 crores due to lower EBITDA and a significant increase in tax provision, as mentioned earlier, in some countries due to non-recognition of DTA, as well as reversal of DTA, which we had recognized in the previous years. Moving on to working capital, net debt, and free cash flows as of end of H1.
The net working capital at INR 14,829 crores saw a significant reduction from previous year H1, where the working capital was as high as INR 20,116 crores. In number of days of sales, net working capital was at 123 days from 149 days in the previous year, a reduction of 26 days. Inventory days stood at 117 days, a reduction of 18 days, while payables days stood at 127 days, which saw an increase of 6 days over that of the previous year. Receivable days stood at 133 days, a reduction of two days over that of the previous year. We also saw a reduction in non-recourse factoring by INR 1,412 crores, about 12 days lower than that of the previous year.
Gross debt, net debt, and free cash flows, due to reduction on account of reduction in working capital and a lower spend on capital expenditure, facilitated the reduction in gross debt by $286 million and net debt by $411 million. With our continued focus on working capital improvement, we are well positioned to achieve our target of 300-400 million of operational free cash flows, which would go to lower the outstanding debt. In absolute values, net debt stood at INR 27,531 crores. That's in US dollar terms at $3.285 billion, as compared to INR 30,697 crores at the end of previous year's first half, which stood at $3.696 billion, showing a net reduction in net debt of INR 3,165 crores. Cash and bank balance as of 30th of September was INR 4,312 crores, as compared to INR 3,237 crores in the previous year.
With this, I hand over to Mike to take you through the UPL Corporation Global Crop Protection Business more in detail. Over to you, Mike.
Thank you, Anand. Hello, everyone, and welcome to our second quarter FY2025 earnings call. It's great to connect again with all of you. Before we review the quarter, I'd like to share my thoughts on the market. Firstly, the fundamentals of the global crop protection market are mixed. With destocking nearly complete, we are now seeing normalized ordering patterns. However, price pressure continues to weigh on the overall market, in part due to overcapacity issues in China and tight grower margins, specifically in global row crops. Finally, we continue to do well in maintaining and growing our market share in most regions. This is demonstrated by the customer preference to our offerings and our higher-than-industry volume growth in our first half of this year. Let's now turn to our financial results for the quarter. I'm pleased to share that our second quarter revenue was up 4% versus last year.
Growth was led by higher volumes across regions such as Latin America and Europe, demonstrating our resilience and rapid recovery from last year's challenging market conditions in these markets. Among major segments, fungicides continued with strong performance. In Brazil, Mancozeb volumes, specifically products such as Unizeb Gold, Manzate, and Evolution, were prime drivers. Europe was led by Proxanil, our premium fungicide for preventative and curative disease control in potato crops. In herbicides, Clethodim led growth in Brazil, but that was offset by overall purchase delays in Argentina and lower volumes in North America. Our insecticides portfolio was affected by price erosion of key active ingredients in Brazil, including Acephate, Acetamiprid, and Imidacloprid. However, this was partially offset by strong volume performance in North America. Revenue growth in our NPP biosolutions business grew by 10% versus last year, driven by biocontrol volumes in Latin America and Europe.
In addition, growth in this business was supported by biostimulants volumes such as nutrients and Biozyme in Brazil. Our contribution margin for the second quarter compressed by around 150 basis points versus last year. You should note that sequentially, we are bridging the gap in our margins, driven by relative margin accretion in most regions. The lower margins in the second quarter versus last year were primarily due to price declines in Latin America countries, along with unfavorable mix in Europe. Turning to SG&A, we are benefiting from operational cost leverage. However, we faced external challenges this quarter from receivable provisions, as mentioned by Anand, which totaled around $16 million. These impacts were mainly in Latin America. Importantly, we continue to improve our product mix towards our differentiated and sustainable segment, with approximately 37% of the first half revenue in this financial year coming from these higher-value offerings.
We are encouraged by this trend and the continued strong adoption by our customers. Let's now review our regional performance for the quarter. In Latin America, our revenues were near flat versus last year, led by higher volumes but offset by price decline. In Brazil, volumes grew by over 30%, mainly from fungicide products. However, price erosion in key products such as Perito, Feros, and Sperto partially offset these volume gains. Argentina was affected due to the shift in sales, with dealers and growers purchasing closer to the soy season, leading to overall revenue decline in the first half. Other Latin American countries were collectively flat versus last year, with higher volumes offset by price erosion. In North America, last year's headwinds resulting from returns and price adjustments have normalized this year.
We continue to see good in-season demand for our products, in particular, insecticides such as bifenazate and acephate had strong volume growth, and were also supported by higher fungicide volumes. Overall, the region grew by around 16% versus last year. In Europe, our revenue was up by around 18%, led by strong fungicide growth. Further, our NPP biosolutions were up by around 25%, driven by strong volume growth. The rest of the world was down by 2%, with a decline in herbicides and insecticides partially offset by fungicide growth. Overall volume growth in Africa was moderated by a decline in Southeast Asia and Japan. Turning to our outlook for Q3 and the full year of FY2025, we continue to expect the price of key AIs to largely remain stable.
With lower input costs, improved product mix, and higher market share in key regions, this is expected to generate margin accretion in the third quarter. While headwinds are expected on account of softness in the ag commodity prices, the freight expenses that were higher in the first half of this year are likely to normalize in the second half to previous levels. Overall, we continue to anticipate normalized margins in the second half, as indicated in our capital markets day presentation. Our team continues to remain disciplined with SG&A, and we are focused on making further improvements in our operating model and driving efficiency throughout the enterprise. We are also reassessing the potential risks of bad debt and write-offs, such as in Brazil, and creating plans to mitigate them.
Overall, our FY2025 focus remains on margins, the benefit of which we expect to get more pronounced in the second half of the year, though the benefit of lower input costs, as well as the impact of new product launches for the fiscal year, which remain on strong footing to deliver $85 million of new revenue. Our strong focus on cash generation continues, and we are optimizing our inventories and other working capital items, as seen in our results. In closing, I want to thank our team and our valued channel partners for the performance in this quarter, and I am confident we will see sequential margin improvement as the year progresses. With this, we are now open for the Q&A session.
Thank you very much.
Thanks, Mike. Just before we get on to the Q&A, let me just provide a quick update on our other three platforms. That is, on our India Crop Protection Business, which now runs under UPL Sustainable Agri Solutions Limited, on our Advanta Seeds Business platform, which is under the Advanta Seeds Limited, and the newly formed SuperFarm platform, which currently, for this quarter, is a part of UPL Limited itself. So going for just a quick business update on UP SAS, the India Crop Protection Chemical Distribution platform, we saw a good rebound in our business in Q2, with revenues at INR 1,013 crore, up by 20% year on year, led by increased volume, primarily in herbicides, as well as overall normalized channel inventory, indicating improved ground consumption of our products.
While sales related to cotton were impacted due to lower spraying in northern India, we had upsides through diversification in other crops, such as rice, maize, and sugarcane. Contribution at INR 304 crores saw a jump of 111% year on year. Contribution margins at 30% were up from 17.1% in the same quarter in previous year on the back of new molecule launches and product mix. SG&A at INR 101 crore were lower by 12% year on year, resulting in a significant improvement in EBITDA and EBITDA margins. EBITDA at INR 203 crores was up by 592% year on year, and EBITDA margins were back to the 20% level. For H1, revenues stood at INR 2,016 crores, flat year on year. EBITDA at INR 372 crores was up by 52%, and EBITDA margins were at 18.5%.
Overall, the team continued its focus on improving the margins with new launches and product mix and working capital reduction through strict credit control and improving collections. Moving on to our seed platform, Advanta Enterprises. After a challenging first quarter, Advanta Seeds platform saw good improvement in Q2. Despite a flat volume, we had a quarterly revenue growth of 4% in Q2, driven equally by price and effects variance. Our revenues were driven by margin accretive growth in grain sorghum in Argentina and Australia, as well as corn in India and Southeast Asian countries. Overall, contribution margins improved by 117 basis points versus last year. We continue to maintain focus on margin improvement and cash generation in this segment, and are confident that this continued momentum is expected to yield favorable results in H2 and for the full financial year. To sum up, revenues in H1 were up.
This is for the overall UPL growth. To sum up, revenues were up in H1 by 5%. EBITDA at INR 2,721 crores sets up well for a 50% growth over previous year, considering the forecast we have for Q3 and Q4, and a reduction in gross debt by $286 million and net debt by $ 411 million ensures that we deliver the free cash flow of $300 to $ 400 million, which should go towards reduction in the gross debt. In summary, business is showing a good recovery in Q2 and H1. With this, I hand over back to the moderator, and we are ready to take questions.
Thank you very much. We will now begin the question and answer session. Anyone who wishes to ask a question may press star and one on the touch-tone telephone. If you wish to remove yourself from the question queue, you may press star and two. Participants are requested to use handsets while asking a question. Ladies and gentlemen, we will wait for a moment while the question queue assembles. The first question is from the line of Saurabh Jain from HSBC. Please go ahead.
Yeah, thank you so much for the opportunity and congrats for broadly good share of numbers and strong recovery in India. My first question is relating to your guidance. While you mentioned about the EBITDA growth and the cash flow guidance, can you also confirm your revenue guidance for the full year, FY 2025, please?
Yeah, sure. Saurabh, thanks for joining us on the call. We continue to maintain our revenue guidance of 4%-8%. As you see in H1, we have already covered 5% growth, so we are pretty much on track.
Yeah, I mean, that is fair. But if I just try to kind of look at how the employee numbers would look for second half of this year, a 10% of revenue growth, assuming a full year revenue growth of 8%, would lead to a 10% revenue growth in second half, which may be possible. But then if I look at the, if I compare this with the EBITDA guidance, if you were to achieve an EBITDA increase of 50%, that would imply the EBITDA margins at about 21% for the second half. What will drive such sharp improvement in EBITDA margins?
So I think there are several factors for this, Saurabh. One is, of course, we are seeing fresh inventory at the current lower cost. So that is one. Most of our high-cost inventory, as we have been reporting, has now been sold. Two is we are seeing a good increase in our differentiated product sales. Those percentages to the overall sales are going up, and these are at improved margins. Third is also the regional mix. We are seeing good recovery in the U.S. As you know, U.S. and Europe both are high margin, as well as in Europe, and both are high-margin geographies. India results, we did announce. You did see the sharp improvement in the EBITDA margins in India. So all these factors give us the confidence that we should be in a position to deliver the guidance, which is of 50% growth in EBITDA.
Yeah, I mean, I can fully agree with that, but 21% kind of an EBITDA margins doesn't sound to be too ambitious, given the current conditions. While there's a recovery, of course, but then going to such sharp normalized margins, back to normalized margins, looks a little far-fetched.
We did a lot of stress testing, to be honest. I mean, before we went to the public and before this call and then the board meeting also, there was a fair amount of discussion. Of course, I'll ask maybe Mike also to chip in, and we also have Ashish here with us, as well as Raj Tiwari, who heads the formulation and the active ingredient business. Pretty much we did a bit of stress testing before we came up with this guidance that we will be in a position to maintain the margins. Mike, if you want to add something, please go ahead.
Sure, Anand, thank you. I'll maybe just add two points to the comments that you made. Firstly, in the second half, which is significantly larger, at least for the global crop protection business, is larger in the second half. And so we do get operating leverage as a result of that, which is helpful to EBITDA margins. And then secondly, as we can see with our fresh inventory, as we liquidated most of our high-cost inventory through the first half, we'll also see a contribution margin expansion in the second half. And so those two things will significantly contribute to the EBITDA margin expansion in the second half.
Yeah, thank you so much. So if we deliver this, then presumably FY2026, EBITDA margins would be better than 20% margins. Is that a fair assessment? Earlier FY2026?
Yeah, so obviously we're not yet guiding to FY26, but look, again, based on our assumption that prices are now relatively flat and we've made the adjustments we've needed to make, we're getting operational leverage in our plants in India with fresh product. And so the sequential margin that we're going to see in the second half should continue beyond the second half.
Thank you so much. The other question is that just seeking some clarity over here. When I look at the UPL level, rest of the world revenues, it is higher by 30% YY. But for UPL Corp, it is lower by about 2%. So this difference, which business segment is this attributed to?
Sorry, can you repeat the question again?
What I'm saying is that if I look at the consolidated UPL Limited regional breakdown, the rest of the world revenue is higher YY basis by about 31%. While UPL Corp, I think the numbers are lower by about 2% for the same geography, rest of the world. Where is the disconnect over here? Where does extra increase, which business segment it is attributed to?
So you have other businesses. For example, your specialty business is there, which is trending much higher than UPL Corp.
But how much would be exported in the specialty business? Because even that business, if I look at the numbers that are reported, that looks like flattish YY basis.
Yeah, on the quarter-on-quarter, it is the revenue is flat, yes.
Yeah, because even Advanta, it would be attributed to Advanta. Even Advanta has shown only a 4% increase YY. So I was just wondering what am I missing over here. Maybe I can discuss it separately with the team. Sure. Thank you so much. I'll turn back to you for more questions.
Thank you.
Thank you.
The next question is from the line of Angel Sun and Prudence Asset Management. Please go ahead.
Hi, Amna. Audible?
Yes, you are.
Yes, please go ahead.
Oh, yes. I just have two questions. One is regarding the rights issue. Is there any update around that? Or have you gotten approval from SEBI? Because per your last press, we didn't know that clear. And also any timeline to guide for the launch moving forward?
Yeah, hi. This is Anand here. You see, as we have a listed entity and we have the regulator, SEBI, as you rightly pointed out, it prohibits us from making any statement on timing of such issues. We'll certainly get the relevant and appropriate updates as prescribed under the SEBI's listing agreement at appropriate time. And I'll be happy to speak to you after such announcement is made.
Okay. So it's right to understand that we haven't gotten any approval. Or you can't comment on that?
I can't comment on that.
I understand. Okay. And then moving on to my second question. In terms of the Advanta seeds business, I think also previously there were some press releases around a possible stake sale or monetization around it. Is there any further updates that you can provide that has happened over the last one or two months since the last update?
No, I think it's work in progress. We are getting our accounts and financial performance for three years and all those things worked out and audited and other details, and we are working on the draft red herring document, so it's work in progress. Again, we will certainly come back to the investing community as and when we have things finalized.
Okay. Yeah, that's all from my side. Thank you.
Thank you. The next question is from the line of Steve Byrne from Bank of America. Please go ahead.
Yes, thank you. Mike, I was curious to hear your view on a potential change in international trade if the red wave in the U.S. were to impose some meaningful tariffs on exports from China into the U.S. Anything in there that might be a potential benefit to you? The other one I was curious to hear your view on is the ITC investigation in the U.S. on anti-competitive trading and contracts with Cropchems. Any involvement with your business on that? And anything I can glean from your outlook for that?
Sure. Hi, Steve. Good to hear from you. Firstly, on the situation in the U.S., obviously with the president-elect Trump coming in on a mandate of trying to make supply chains more resilient and less dependence on China, I think that would bode well for UPL. Obviously, as an India-based manufacturer, we're prepared to continue to grow our business if the opportunity presents itself in North America. So look, I think we have to see how the policy comes forward and what impact there may be on crop protection products that are coming from China. If there is increased tariffs, then that would, again, bode well for us. On the second question, Steve, the investigation from the federal government that's happening right now with respect to a couple of our competitors in the market that they're looking at anti-competitive behavior, what is so-called loyalty programs.
Again, that's out of our control. We're watching and waiting how that proceeds. I would say from our perspective, if the loyalty programs were found to be anti-competitive and if they were to go away, that again would open up additional opportunities for us in North America, in the U.S. in particular, not just with our post-patent business, but also with some of our differentiated products, which also get, unfortunately, hung up competing against some of those loyalty programs. And so again, that would be a positive turn of events for us if and when that were to conclude.
Very good. Thank you for that. And maybe a couple of outlook questions for you. One being in biologicals, you have some strong growth there. You commented on biostimulants. But what about anything in your pipeline you're particularly excited about in biologicals? Anything that you'd like to comment on there? And then the other one would be in Advanta Seeds. The European Union is certainly looking at a more favorable regulatory scheme on using gene editing in seeds. Is that a potential benefit to your seed business?
Great. So Steve, that answers the question with respect to the seed business. On biologicals, as you mentioned, we saw strong growth on a year-to-date basis, and again in our second quarter. Biostimulants was a part of that. But as I mentioned, we also saw significant growth in our biocontrols business, specifically in Europe, with that business up over 25% on the quarter. And so we have a very robust portfolio. We do have some very exciting new products that are coming through the pipeline, which include biostimulants and biocontrol products. This year, of the $85 million of new product revenue that we're expecting, over 80% of that is in the categories of differentiated or sustainable products. And so again, as we look ahead in our pipeline, over 75% of our pipeline is differentiated, like biosolutions or sustainable products or differentiated products.
And so our whole pipeline is really geared towards that segment. And so we do expect to outpace growth in our business in our biological and sustainable portfolio, just as we have in the first half of this year. Bhupen, I'll turn it over to you on the gene editing question for Europe.
Yeah, Mike. Thank you so much. Can you please repeat your question here on gene editing?
It's a broad question. Is it a technology that you see meaningful benefit to you in your seed business? And then more significantly, the regulatory outlook really varies geographically. It's quite streamlined in the U.S., but it's currently effectively blocked in Europe. But that potentially is changing in another year. Any benefit to you on any of that?
I think from a technology point of view it is very beneficial technology. We keep an eye on it. Last time when we reviewed, globally, nearly 900 gene editing projects are going on. A very important aspect is out of that, more than 509 are only in China. So this is a very exciting technology and they're progressing very well. Your question is related to the regulatory aspect of it. We just participated in the European Seed Conference last week, and while the regulatory pathway is clear, but still some of the industry is concerned that they are asking a lot of questions there. So the pathway has to be evolved fully for further progress in gene editing in European countries.
Very good. Thank you.
From Advanta's point of view, I can add one small piece of fact. We are already working with some of the Australian universities to enhance the size of the sorghum grain and increase the protein content, and for that, we are using the gene editing tool benefit in collaboration with the Australian university, and the project is progressing quite well.
Great. Thank you.
Thank you, Steve.
Thank you. The next question is from the line of Lynn from BNP. Please go ahead.
Hi, can you hear me?
Yes, go ahead. Yes.
Just a follow-up question on the rights issue. I think the company previously announced that you have made progress for the rights issue and you plan to make a necessary announcement after the publication of the UPL results. So now that the UPL results are published, I just want to clarify if we should still be expecting this announcement about the rights issue and so is it further delayed?
As I mentioned earlier, to a question from another investor, I think we are constrained as we are a listed entity. And the regulator that SEBI regulations prohibit us from making any speculative statements or any statements on the timing of such issue, which could be construed as speculative in nature. So certainly, I'll be happy to speak to you all once we make the announcement, and we can then discuss further on that.
Sure. Thank you. And my next question is regarding the rating agency. So I note that Moody's still has you on negative rating watch due to some concerns on refinancing and upcoming loans. So how has the latest communication with Moody's been?
Oh, I think the communication is very healthy. We are engaged with all the three rating agencies, and we are in regular touch with them. So I think whatever information they wanted, we have been sharing in a transparent way. And things are I mean, they understand what's going on in the industry. Within that, I think our performance is fairly good, and they're happy to continue to engage with us on a regular basis. So I would say nothing of any cause of concern, at least at this stage. At least that's the impression I have after communicating with them.
For the refinancing of the loan, is there really a problem anymore for Moody's?
Oh, that we have already made arrangements, and we have shared the details with Moody's on that.
Sure. Thank you. And on my last question, I just want to get a sense of what is the change in volume and price on a quarter-on-quarter basis? I think in the presentation, it's more of a year-on-year basis.
I didn't understand your question. You are referring to what is the volume growth?
Yes. Volume and price change on a quarter-over-quarter basis for the revenue variance.
So on Q2, we saw a growth of volume of about 16%, and there was a price degrowth of 9% and 7%, sorry, a price degrowth of 7%. Whereas for first half, again, we saw a volume growth of 16% and a price degrowth of 9%. Yeah.
This is on a year-over-year basis, right?
That is right. Compared to previous year, same quarter or same first half.
I see. Do you have a quarter-over-quarter basis versus first quarter of FY2025?
No, we don't compare that due to the seasonal nature of our business. The business is seasonal, and therefore, it's always better to compare with that of the previous year. I just compared the EBITDA margin improvement just to show that every quarter we are seeing an improvement in the EBITDA margins and thereby assuring that we are moving in the right direction in terms of both the EBITDA as well as the free cash flow generation.
Sure. Understood. Okay. That's all from me. Thank you so much.
Thank you.
Thank you. The next question is from the line of Antonio Gomes from Ninety One UK Limited. Please go ahead.
Hi there. Thank you for your time. Follow-up from a couple of questions from the previous person. So firstly, on the refinancing of your short-term loans, can you confirm whether or not you have been able to refinance them? And if so, could you share some broad terms?
I can confirm we have been able to refinance this loan, but we haven't drawn down, and we won't be in a position to share the terms and conditions of this loan.
Okay. That makes sense. Thank you. The second question that I had was with regards to the rights issue. Previously, you had been providing information on the timing of when you expected this to close, at least on a broad basis. And it seems since you issued the press release saying that you were going to do it after the Q2, that something has changed with regards to what you can or cannot share. Could you just provide a little bit more detail as to why your disclosure has changed and effectively you can't share with the market when you expect this rights issue to occur?
I think nothing has changed. It's just that we will come with the disclosure shortly. There is a procedure being required after the announcement of the quarter numbers. We are following that process, and we will come with the updates shortly.
Okay. Okay. That makes sense. Those are the main questions for me. Thank you very much.
Thank you for joining us.
Thank you. The next question is from the line of Love Sharma from JP Morgan. Please go ahead.
Hi, Anand. Thank you for the call. Just a couple of questions from me. First one, maybe on the Q3 trends, if you could indicate, given I think you reiterated the guidance for EBITDA 50% YOY growth, would like to understand what are you seeing in terms of pricing and volumes for Q3? And the disease situation in Brazil, is that improving or any changes there in this quarter which you expect?
I'll hand over to Mike because that's a large part of our business, and maybe Mike, if you can share some insights into Q3 forecasts.
Yeah. Very good. Thank you for the question. As you've seen from the first half, we had very significant volume growth of 18% and price compression of 13%. Our expectation as we go into the second half of the year is that both of those trends will start to reduce. Our volume growth will no longer be in the double-digit range. It'll likely be kind of in the mid-single digits. But likewise, the pricing headwinds that we've experienced in the first half will largely dissipate. Again, if you just kind of rewind the clock, in the second half of last year, we really had reset our pricing, which also created an issue where we also had a number of channel rebates that were also triggered as a result of that.
So with those headwinds behind us, that's one of the reasons why we're expecting to see significant contribution margin growth as we go into the second half. And ultimately, leverage from our SG&A will also see EBITDA growth. So that's largely what we're expecting from a volume price standpoint in Q3 and in H2. To your second question with respect to Brazil, there's been a number of issues, not just one. There was one very large distributor that filed for Chapter 11, but there was about a dozen other smaller distributors that have also filed to reorganize. A lot of that has happened in this past quarter and some of it in the first quarter of our fiscal year.
We would anticipate now that the retailers that haven't restructured are either serving their customers, they're in the process of selling crop protection products and other inputs as the season is now unfolding, and so as we see the strength of those companies, and obviously, we're watching the credit risk very closely, we would anticipate that we're not anticipating any other major restructuring from any of our major customers. That being said, grower margins continue to be squeezed, especially for corn and soybean growers. In Brazil, in particular, the weakening of the real versus the U.S. dollar is helping growers a little bit with their margins, and so, yeah, this is a situation that I would say has some risk to it. Right now, soybean planting is on pace, which is good.
And so assuming an average or better than average crop, the growers will have liquidity to pay their dealers, and then likewise, their dealers will pay us as the season unfolds. But yeah, I would say that's the scenario that's kind of playing out right now as we go into the second half of the year.
So thanks, Mike. Just maybe as a follow-up, so given these challenges which you are seeing somewhat on the receivable side and also at the distributor's level, does it not impact your expectation for how Q3 would unfold potentially in terms of revenue and even pricing, perhaps?
No, because really what's happened, and this is course-corrected over the last 18 months, is the channel distributors and the growers are now buying just before they need the product, and so we have a healthy order book right now in Brazil that's going to really help us finish out the third quarter and start into our fourth quarter of next year, so we can see that the order book is healthy, and growers are ordering as they need products, and so now that soybeans will be largely planted over the next couple of weeks, we'll move into herbicide, insecticide, fungicide season, and as those growers need those products, they'll be going to their retail channel.
Some of that is already on the shelf, but a lot of it is going to still be ordered as the season unfolds this year, which is, again, a difference in timing versus the last couple of years, and that's why we would anticipate some growth in Brazil as the season unfolds here ahead of us.
Understood. Okay. Thanks. This is useful. And just one more question from me. Again, kind of similar to this. I think there is still continued reduction in your factoring. Maybe question for Anand. How does it look for going forward on a three-to-two basis? And does the dismal situation in Brazil have an impact here?
I think limits are intact for factoring. We just were reducing our cost of borrowing marginally when the factoring cost is marginally higher as compared to a plain vanilla borrowing. We do a mix of both. Where we see the risks are high, we try to push it on the factoring because we have seen that the behavior of the customer in making payments on due dates is very different when his receivables or his payables are factored with the bank. We do it selectively, but we will continue to do it. As you know, we have guided for $1 billion of factoring by the end of this financial year. I think we should be in that range.
Thanks. I just wanted to ask a question. How much is Brazil of this outstanding factoring which you have right now?
I don't have the number offhand, but I think about 50% should be Brazil out of this. We have close to $500+ million. 50% should be Brazil.
Got it. Got it. Thank you so much.
Thank you.
Thank you. The next question is from the line of Shashank Agarwal, an individual investor. Please go ahead. Shashank, please go ahead with the question. Your line is unmuted. Shashank Agarwal, may we request you to unmute yourself and proceed with the question? As there is no response, we will move to the next question, which is from the line of Sonali from Jefferies. Please go ahead.
Hi, Anand and team. Thank you for the opportunity. So firstly, I would like to confirm the FY2025 guidance that you just gave out. So it is 4%-8% year-on-year revenue growth, 50% year-on-year absolute EBITDA growth. And I missed the numbers for FCFF, net debt, and gross debt reduction.
We said we will be guided for a free cash flow of $300-$400 million, which would be used to repay the debt.
And the net debt reduction guidance is?
$300-$400 million, right?
Okay. Okay. Understood. And the CapEx one?
CapEx, we have guided for about INR 1,800 crores. Although for the year, up till now, for six months, we have hardly spent about INR 700 crores. So we are well within the budget.
Understood. The second thing is in terms of destocking, you did mention that destocking is nearly complete. So how many more months do you think before the normalized growth kicks in?
Mike, if you can. Mike and maybe Ashish to cover for India.
Yeah. So excluding India, again, as I had mentioned earlier, that we believe that destocking is largely behind us. And as seen in our volume growth year to date of 18%, it's an indication that we are increasing our sales from a volume standpoint, although I believe that would be an industry-leading volume growth. So I think we're now largely into normal ordering patterns. And so we wouldn't be expecting to see destocking impact our business in the global crop protection business going forward.
Understood, so then last thing, your rights issue, we understand you cannot comment on the exact timeline, but just wanted to cross-check. The issue is worth $500 million, right?
No. We had said up to $500 million. I think the board has come back with a guidance of about $400 million. So the issue now we plan to come up with is $400 million.
Understood. Thank you, sir, and all the best. So sorry, last one. Sorry. Average cost of debt in Q2 versus last year?
It's around 7%.
Last year?
Last year, we did not see the increases, so it was around 6.25%.
Understood. Thank you, sir. All the best.
Thank you.
Thank you. The next question is from the line of S. Ramesh from Nirmal Bang Equities. Please go ahead.
Thank you very much. Good evening, Anand and Mike. So in the UPL Q2 numbers you have shared for second quarter of first half, can you give us how much of Advanta Seeds' international revenues included there?
UPL Corp numbers don't include Advanta numbers. UPL Corp, what we shared is UPL Corp's number. That is our crop protection business, global crop protection business ex India, without India.
Okay. So that is only crop protection. Okay. Second thing is, if you look at the kind of volume growth you're talking about, double-digit growth in first half and then single-digit growth second half, on that base, what is the kind of ballpark volume growth we can expect assuming normal conditions of consumption and weather, say, for FY2026? Any sense you can give on that?
Mike, you want to take this question?
Yeah. Look, I mean, I think if you look at the grower demand for global crop protections, I mean, every year, we would expect to see somewhat of an increase as planted areas continue to go up in countries like Brazil. But again, it's in the low single digits. And so again, as I would think about FY2026, volume growth will again likely be, I'd say, 5% or less.
And so in terms of pricing, when do you think we'll get some positive contribution from pricing? Will it be first half of next year, second half? What is the ballpark sense you get on pricing power coming back?
Look, the current situation with overcapacity in China, that's likely to persist for some time. And so from a base case planning standpoint, we really do believe prices are at the bottom, and we've seen that. And in fact, for the last several quarters, prices coming out of China have been relatively flat. So if your question is, at what point would we expect an increase in those prices, it's really hard for us to predict that. So our planning scenario is based on relatively flat prices out of China. Our supply chain teams are doing a great job of further debottlenecking and finding cost opportunities in our own supply chain. And so again, even at these prices, and we'll see this in our second half, our margins will really come back to a more normalized range. And again, we would expect that to continue into the future.
That's useful. One last thought on the balance sheet. So if you exclude the rights issue proceeds and any monetization of Advanta, what is your internal working on the net debt target for March 2025?
It should be just around the 2-2.2 level, net debt to EBITDA. And once the rights proceeds are in, maybe we should be below 2.
Thank you very much and wish you all the best.
Thank you very much.
Thank you.
Thank you. The next question is from the line of Abhijit Akella from Kotak Securities. Please go ahead.
Yes, hi. Good afternoon. Thank you. Just a couple from my side, Anand. One is the UPL Specialty Chemicals numbers in the presentation seem to have been adjusted quite significantly from last year. The 2Q FY2024 numbers, the year-ago numbers, these have been adjusted quite significantly downward. So just trying to understand what the changes made there might have been.
Yeah, the overall price table was. Sorry, guys.
Because of the formulation business now.
Okay. There are two reasons for this. One is the formulation business continues to be with UPL Limited, whereas the specialty chemicals business will have active ingredients, and the other specialty chemicals which we sell to the paint, pharmaceutical, and lubricant industry. That's one. Two is, of course, we saw the overall price table also coming down with the reduction also in the cost of manufacturing and the cost of raw material. So these two factors led to a drop in revenues as compared to previous year.
No, actually, sorry, just to make my question a little bit clearer, the numbers for the spec chem business last year, for example, Q2 FY2024 were INR 3,500 crores. And I think this time around we've shown a number of about—sorry, just pulling it up here. It is about.
INR 2,600 crores this year.
Yeah, yeah. So why that reduction compared to?
That is because of the fact that remember that the UPL specialty chemical business last year, the numbers, what, INR 3,500 crores were reported, also includes the formulation that used to get done or gets done and supplied to UPL SAS and UPL Corp, right? That formulation business is part of UPL Limited and not part of specialty because specialty is only now advanced intermediate, advanced tech, advanced intermediate, and specialty chemicals. So both numbers are not comparable.
Okay. So this excludes the formulations business.
That is correct. Yes.
Got it. Okay. And the other question was just with regard to the tax rate. So what exactly has led to the derecognition and disallowance of these different tax assets? And what's the normalized tax rate we should be working with for the full year now?
We have just been conservative, and therefore we reverse the DTA. And I think the tax rates would vary from country to country, needless to mention, because each local entity will have their own tax rates. But at an average, we say, as we always have guided, our tax rate would be in the range of about 18% at a consolidated level.
Okay. Got it. Thank you so much and all the best.
Thank you very much.
Thank you. The next question is from the line of Vikash Agarwal from Bank of America. Please go ahead.
Hi. Can you hear me?
You're sounding very low, sir.
Thank you. Thanks for the call. Hi, Anand.
Hi. Yeah, good. Vikash, you're sounding a bit low. If you can come closer to the phone or.
Is it better now?
Much better. Thank you.
Perfect. Anand, a couple of questions from our side. One is a question on the customer filing for bankruptcy or the distributor filing for bankruptcy. What was the revenue exposure we had to that customer?
Revenue exposure. Maybe relevant would be what was the outstanding. We had close to about $15 million of outstanding, out of which $8 million we recovered from the insurance company. I mean, we had the process, and the balance, we have made a provision in the books.
Got it. And just in terms of impact of such large distributors filing for Chapter 11, how should we think about overall business impact or any disruption, even if temporary, on the supply chain?
Maybe I can take that.
Yeah. Go ahead, Mike.
Yeah. Yeah. So Vikas, obviously, the growers are going to still need the inputs, whether it be seed, fertilizer, or crop protection products. And so the growers are still going to access those technologies. And so obviously, by restructuring, that company is still operating, but probably with not full shelves of products. And so if one of their customers needs to go to another distributor, that's what they'll do to get the products. And again, that's quite typical. Lots of growers will buy from two or three different retailers. And so we would expect those growers to continue to buy UPL products. And if they can't get them from this distributor, then they'll go to other distributors to procure them.
Got it. That's helpful. And Anand, one last question.
As we have said always, we do take credit insurance on most of our customers. So we continue to do that.
Sure. And one more, just a basic question, Anand, is when I look at the contribution margin impact on a quarter for the second quarter of FY2025 on a year-end basis, this is about 150 basis points lower for UPL Corp. And for most of the segments, it's actually higher. But when I look at on a UPL group level basis, the contribution margin is about 220 basis points lower. So can you help me understand how should I think about it?
Basically, a large piece, almost 80%-85% of our business is UPL Corporation Cayman business, right? That has its influence on this. Again, those are in dollars, which we converted, but when you put it in, also when you see when you convert it into INR, there could be some impact over there also, the currency impact, so broadly, basically, I mean, there will be consolidation adjustments also, which would happen as we consolidate the financials from each of these segments.
Sure. Okay. Makes sense. And.
Also, there are some utilization of capacities, which would have also knocked out part of the margins at India level.
Got it. Got it. And sorry, one more last question from my side is just listening to some of the previous response on the pricing impact in the second half. So is it fair to say that now where we are in terms of pricing in the current quarter or the exit quarter, and then when we compare it to the second half of FY2024, the negative impact is not expected to be much larger on a year-on-year basis in the second half of FY2025?
Yeah. I think we took a large knock. If you see our Q3 numbers last year, we had a drop in EBITDA by about 80%. Now, that was because we had to offer special rebates to our large distributors and customers who had high-cost inventory left with them and support them in helping them to sell the inventory, which was there with them. We also had inventory with us, which was high-cost inventory. And in order to sell those inventories, we had to mark-to-market them down, considering what were the price levels that were prevailing at that point of time. So those things are now past us. Most of our inventory is fresh inventory.
You heard me also say that our inventory number of days has significantly reduced because our team is managing the inventory very tightly, both be it at our country level or be it at the manufacturing level, so all those things, at least we don't foresee in Q3, Q4 this year, and that gives us the confidence of delivering the margins.
Perfect. Thank you. Sorry, if I can ask one last question, in terms of the high-cost inventory, is there a balance which you can share?
I think it should be less than $20-$30 million out of the close to a billion inventory which we already have.
Got it. Okay. Thanks a lot, Anand. This is very helpful. Thank you.
Thank you.
Thank you. The next question is from the line of Varun Ahu ja from BlackRock. Please go ahead.
Hi. Most of my questions have been answered. Just one or two things. One is, given the tight inventory management and overall working capital management, is it fair to say that the typical cyclicality and hence the reduction in working capital and associated debt that we see in the second half, we'll start seeing that to be lower as well, and just the overall movements will tend to be lower. That's one. Secondly, in terms of the drivers for 50% increase in EBITDA year-on-year, can you give us a bit more color on the visibility towards that? Is it just that you have more, as you mentioned, tighter inventory, just in-hand inventory? So that gives you a lot more visibility plus the volumes growth, or there are other factors at play? Thank you.
No, I think on the first question, I think it's just that we brought in more efficiency in our inventory management. I would put it that when everything we saw great growth, we grew twice what we had projected or what we had guided for growth during the COVID time, and obviously, everything was looking good, and there was some laxity in inventory management, if I were to put it, in hindsight, but I think we are trying to bring in more efficiency in inventory management. The cyclicality of business continues to remain, but that's where the skill lies that if we can manage the inventory levels and ensure that we don't lose space is what we are trying to aim for. On the second piece, I think we knew that we had hit the rock bottom last year. Things would only improve from there.
But at the same time, last year, we took close to about a hit of about $392 million on our contribution and P&L, which was arising due to giving special rebates to our customers for what we had sold in the previous year. That's in the year 2022, 2023. And we had to also do a mark-to-market of the inventory which we were holding effective 1st April 2023. So those, obviously, we had to take the hit off those, which totaled to $392 million. And we knew that this year, when we started the financial year, we had only about $60 million of high-cost inventory left. The rest of the inventory was all fresh inventory. And also, it's obvious that if we start managing the inventory better, we would have fresh inventory, which would be obviously the new cost, which were much lower costs.
So both these factors, because of both these factors, we don't expect this year that $392 million hit or a similar amount of hit to come by. And that gives us assurance that we should be in a position. Last year, we delivered EBITDA of $666 million. If you add this $392, it takes us to $1 billion. And that's slightly higher than the 50% growth that we have indicated over last year, the growth in EBITDA. So that's the broad math which we have done before we give the guidance.
Thank you. That's helpful. Just one follow-up. I understand you can't comment on the rights issue. On other inorganic exercises, including the seed business, any updates on that, or really what's the thought process with the recovery in industry that you're expecting? Is that still going to be a priority, or it's more of a wait-and-watch on the right valuations?
No, I think we continue to explore opportunities. And yes, things take a bit of time. But we continue to explore opportunities. And we would just request patience. We will come with updates as soon as we have clarity around some of these things. But I mean, you know it very well how M&As and other things take place. Until unless it's signed, there's no point talking about it.
That's fair. All the best, and thanks so much.
Thank you very much.
Thank you. The next question is from the line of Samuel Chen from AllianceBernstein. Please go ahead.
Hello. Can you hear me?
If you can speak a bit louder, sir.
Hello. Hello. Can you hear me? Hello.
Also, can you please speak a bit louder? Can you please be a little loud?
Sure. How about now?
Yes. Please go ahead.
Good. I just have one question. This one's probably for Mike. I would like to know, on a six to 12-month basis, if you were to rank the regions under the coverage, which regions are you more optimistic, and which regions are you a little more conservative? Thank you.
Yeah. Good. Thank you for the question. Look, if we look backwards, the regions that were problematic for us last year were really LATAM, and within LATAM, it was Brazil, North America, and Europe. This year, we're seeing turnaround strength in Europe and North America, and we expect the same for Brazil as the year unfolds. I think so, looking over the next 12 months, and again, based on our new products that we've launched this year and we're launching next year, we would expect to see growth in every region. This is a perfect question because this is the time of year where we're starting to work on our budget planning for FY2026, and so I don't foresee any regions where there's structural or fundamental issues.
I think, again, with destocking behind us and assuming relatively flat pricing for AIs coming out of China, the improvements we made in our supply chain, the improvements we made in our operating model, and cost leverage, I think we're set to compete very aggressively going into the future. And so I would rank all of our regions with opportunity to grow over that timeframe.
All right. Thank you, Mike. And then if I can just one follow-up. You mentioned about active ingredients. I know they're both your competitors, but you also source some active ingredients from them as well. So it's kind of like there's on the revenue side and the cost side for you. I'm not looking for a number. I'm more looking for direction. For example, if the active ingredient price I know there are many active ingredients, but on average, if the active ingredient price were to increase, do you got to net the quarter to UPL and then vice versa on the other side? I just want to see a directional sense.
Yeah. The way I think about that, it's a good question. The way I think about that is we can see that across our portfolio, whether it's insourced or outsourced, our margins are roughly in the mid-30s%. And I think that's consistent. Obviously, when you go through a shock, either a cost up or cost down, you'll get disruption in that. But once you're in a stabilized environment, that kind of mid-30s% margin opportunity based on our customer intimacy, the brands that we have in the marketplace, the go-to-market model, I think that margin should be consistent. So obviously, if you're in a higher-cost environment, over time, if the margins are the same, you're going to put more dollars on the bottom line. So that's why at this lower-cost environment that we're in today, we talk about getting our margins normalized.
But again, that's come with some trimming on the top line from an absolute basis. And of course, that flows through the margins as well.
Sorry, I didn't follow 100%. So in the current environment where active ingredients, where the active ingredients are low price, and then we're in the process of seeing margin recovery here on our side as well. If the active ingredient price were to increase, technically, it will push down your cost a bit, but it will also allow you to sell a bit higher. Would I be seeing margin expansion in general?
Yes, I agree with that premise. Although there's always some lag time as the market catches up because if prices are going up, depending on competitive market environments, it may not be instantaneous, of course, that you can increase prices. And so that's all I'm saying is through that disruptive period, margins can get depressed. But assuming we can maintain a mid-30s% margin in our UPL core business, then as prices go up, from an absolute standpoint, what you're saying is true, that absolute margin dollars will go up as well.
Okay. Thank you. Thank you for your time. All the best.
Thank you.
Thank you. Ladies and gentlemen, this was the last question for today. I would now like to hand the conference over to the management for closing comments.
Thank you very much, all of y'all, for joining us on the call. In case if there's any follow-up question, please reach out to Varuna or myself, and we'll be happy to provide you the answers. Thank you very much.
Thank you. On behalf of UPL Limited, that concludes this conference. Thank you for joining us, and you may now disconnect your lines.